Haloperidol Dose for Rapid Tranquilization
For rapid tranquilization of acutely agitated adults, use haloperidol 5 mg intramuscularly, which can be repeated every 4-8 hours as needed, though doses may be given as frequently as every hour based on clinical response. 1
Dosing Algorithm
Initial Dose
- Standard dose: 5 mg IM is the most evidence-supported dose for acute agitation 2, 1
- Lower dose: 2 mg IM is appropriate for debilitated, geriatric, or patients with history of adverse reactions to antipsychotics 1
- The FDA label explicitly states 2-5 mg IM for "prompt control of the acutely agitated schizophrenic patient with moderately severe to very severe symptoms" 1
Repeat Dosing
- Subsequent doses can be administered as frequently as every hour if needed 1
- More commonly, 4-8 hour intervals are satisfactory for most patients 1
- Monitor clinical response to determine timing of repeat doses
Evidence-Based Context
The 5 mg dose has the strongest evidence base across multiple studies. The ACEP clinical policy guideline demonstrates that haloperidol 5 mg was consistently used in Class II studies comparing it to benzodiazepines (lorazepam 2 mg) and showed equivalent efficacy 2. Studies comparing haloperidol to droperidol also used 5 mg as the standard dose 2.
Important consideration: While 5 mg is standard, combination therapy often proves superior. The combination of haloperidol 5 mg + lorazepam 2 mg produces more rapid sedation than either agent alone 2, 3. One high-quality multicenter trial found the combination achieved faster tranquilization at hours 1-3 compared to monotherapy 3.
Special Populations
Geriatric Patients (≥65 years)
- Start with 0.5-1 mg IM 4
- Evidence suggests low-dose haloperidol (≤0.5 mg) is similarly effective to higher doses in older adults with better safety profile 4
- Geriatric patients require more gradual dosage adjustments 1
Debilitated Patients
- Use lower end of dosing range (2 mg IM) 1
- Titrate more cautiously based on response
Critical Safety Considerations
Extrapyramidal symptoms (EPS) increase with higher doses. Studies show that doses >7.5 mg/day significantly increase clinically significant EPS compared to lower doses (NNH = 3) 5. The 5 mg dose represents a balance between efficacy and tolerability.
QTc prolongation: All antipsychotics prolong QTc interval at maximum recommended doses, though none exceeded 500 ms in studies 2. Consider baseline ECG in high-risk patients.
Avoid epinephrine if hypotension occurs—haloperidol blocks its vasopressor activity. Use metaraminol, phenylephrine, or norepinephrine instead 1.
Route Considerations
While the question asks about rapid tranquilization (implying IM route), the FDA label specifies IM administration for acute agitation 1. IV haloperidol is used off-label but carries additional cardiac risks and requires closer monitoring.
Transition to Oral Therapy
Switch to oral formulation as soon as practicable. The parenteral dose given in the preceding 24 hours provides an initial approximation of total daily oral dose needed. Give first oral dose within 12-24 hours following last parenteral dose 1.
Common Pitfalls to Avoid
- Don't exceed 7.5 mg/day without clear justification—higher doses increase EPS risk without proven additional efficacy 5
- Don't use as monotherapy when combination therapy is feasible—haloperidol + lorazepam is more effective for rapid tranquilization 2, 3
- Don't forget anticholinergic prophylaxis consideration—though not routinely required, have diphenhydramine or benztropine available for acute dystonia
- Don't ignore alternative agents—droperidol 5 mg produces faster sedation than haloperidol 5 mg if rapid sedation is the priority 2